Group 1 - The core viewpoint of the article is that the company, 港通医疗, is focused on providing medical gas equipment and systems, as well as clean medical equipment and systems, which are integral to the construction of smart hospitals [1] - The company is actively monitoring the development of AI in healthcare and is committed to enhancing the intelligence level of its products to meet the growing demands of modern hospital construction [1] - 港通医疗's response indicates a dedication to addressing medical gas supply and infection control issues within healthcare institutions [1]

Core Viewpoint - The U.S. President Donald Trump announced that Venezuela will use the proceeds from the sale of up to 50 million barrels of oil to purchase only American-made products, strengthening economic ties between Venezuela and the U.S. [1][3] Group 1: Economic Relations - The purchases will include American agricultural products, manufactured drugs, medical devices, and equipment for improving Venezuela's electrical grid and energy facilities [1][3] - Trump has been pressuring Venezuela's interim president, Delcy Rodriguez, to enhance economic relations with the U.S. following the military capture of Nicolás Maduro [1][3] Group 2: Oil Sale Details - Venezuela's oil assets, valued at approximately $2.8 billion based on current market prices, will be released to the U.S. [1][3] - To protect the funds from Venezuelan creditors, the proceeds from the oil sale will be deposited into a U.S. Treasury account [1][3] Group 3: Global Oil Sales - The White House Press Secretary, Karine Jean-Pierre, announced that the U.S. has begun selling Venezuelan crude oil globally [2][4]

Group 1 - Guizhou Er Yi Medical Technology Co., Ltd. is focused on the production of medical protective clothing and isolation gowns, with a target output value of 100 million yuan for the year, and orders already booked until March [1] - The Shiwangguo Group's 5G smart factory has achieved an annual output value exceeding 800 million yuan from the production of processed products from prickly pears, benefiting over 20,000 local farmers [1] - The construction of the Qiannan Pumped Storage Power Station is a key project under the national "14th Five-Year" energy development plan, with 80% of the main engineering completed and expected to reduce carbon dioxide emissions by 1.6 million tons annually upon completion in 2027 [1] Group 2 - Qiannan Prefecture has initiated a series of consumption promotion activities with a budget of 30 million yuan, aiming to boost consumption by over 500 million yuan through various measures including subsidies and promotional events [2] - The economic work meeting in Qiannan has set clear development directions and paths for 2026, emphasizing high-quality development and the implementation of the "316" overall deployment strategy [2][3] - The focus on enhancing the real economy includes strengthening industrial growth, optimizing agriculture, improving tourism, and expanding the service sector, while also fostering new industries and building a green manufacturing system [3]

Group 1 - The core stock price of Leksin Medical (300562) closed at 13.93 yuan on January 7, 2026, down by 1.42% with a turnover rate of 3.6% and a trading volume of 58,300 shares, amounting to a transaction value of 81.63 million yuan [1][2] - On January 7, the net outflow of main funds was 1.12 million yuan, while the net inflow of speculative funds was 3.60 million yuan, and the net outflow of retail funds was 2.48 million yuan [2] Group 2 - Leksin Medical announced the use of idle raised funds totaling 129 million yuan to purchase principal-protected floating income structured deposits, which are linked to the AUD/USD exchange rate, with a term until April 15, 2026, and an expected annual yield of 0.50% to 1.80% [1][2] - The company has completed the necessary approval procedures from the board of directors, supervisory board, and shareholders' meeting for this investment, ensuring that the use of raised funds remains unaffected [1] - The company has implemented multiple measures to control investment risks, including tracking project progress, internal audit supervision, and information disclosure [1]

来源：证券时报 证券时报记者 吴瞬 2025年，港股IPO以总计2858亿港元的募资额重登全球首位，成为全球资本市场中最亮眼的存在。进入 2026年，这一势头进一步强化：开年之初，国产GPU企业壁仞科技以及大模型企业智谱AI与MiniMax便 集体登陆港股市场，为全年市场奠定了鲜明的科技基调。 目前，港交所排队上市企业数量超过300家，形成了庞大的后备上市梯队。其中，科技与A to H（即A股 企业赴港二次上市）将成为贯穿2026年港股IPO市场的两大核心主题与关键驱动力。多家市场机构预 测，2026年港股IPO募资规模有望延续强势，并突破3000亿港元。 底气充足 IPO热潮有望持续 超过300家的排队企业，为市场带来了显著的增量预期和活跃度的确定性。据了解，排队名单呈现明显 的"龙头聚集"效应，无论是新兴赛道还是传统行业，均不乏各领域头部企业，如半导体领域的硅基智 能、新零售领域的鸣鸣很忙、新能源领域的岚图汽车、医疗器械领域的迈瑞医疗等，为港股市场注入了 优质资产。 再迎递表高峰 300余家企业排队上市 港交所披露易显示，截至2025年底，排队等待上市的企业数量达到316家。在2025年末至2026年初之 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603309 证券简称：维力医疗 公告编号：2026-003 广州维力医疗器械股份有限公司 2025年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 业绩预告的具体适用情形：实现盈利，且净利润与上年同期相比下降50%以上。 ● 广州维力医疗器械股份有限公司（以下简称"公司"）预计2025年度实现归属于母公司所有者的净利润 为7,500万元到9,500万元，与上年同期相比，将减少14,439万元到12,439万元，同比减少66%到57%；预 计2025年度实现归属于母公司所有者的扣除非经常性损益的净利润为6,500万元到8,500万元，与上年同 期相比，将减少14,502万元到12,502万元，同比减少69%到60%。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 经财务部门初步测算，预计2025年度实现归属于母公司所有者的净利润为7,500万元到9,500万元，与上 年同期相 ...

蓝帆医疗股份有限公司 第六届董事会第三十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 蓝帆医疗股份有限公司（以下简称"公司"）第六届董事会第三十七次会议于2026年1月4日以电子邮件的 方式发出通知，于2026年1月7日以通讯表决的方式召开。本次会议应参加会议董事8人，实际参加会议 董事8人，全体董事以通讯的方式出席会议。公司董事长刘文静女士主持了本次会议。会议的通知、召 开、表决程序符合《中华人民共和国公司法》和《蓝帆医疗股份有限公司章程》的规定。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002382 证券简称：蓝帆医疗 公告编号：2026-003 债券代码：128108 债券简称：蓝帆转债 二、董事会会议审议情况 1、审议并通过了《关于董事会提议向下修正"蓝帆转债"转股价格的议案》； 截至2026年1月7日，公司股票已出现连续三十个交易日中至少有十五个交易日的收盘价低于当期转股价 格85%的情形，已触发"蓝帆转债"转股价格向下修正条件。 为充分保护债券持有人利益，优化公司资本结构，支持公司长期 ...

Core Viewpoint - Boston Scientific (BSX) is showing potential as a stock pick due to its recent technical performance and positive earnings estimate revisions [1][3]. Technical Analysis - BSX has surpassed the 50-day moving average, indicating a short-term bullish trend [1]. - The stock has increased by 5.7% over the past four weeks, suggesting upward momentum [2]. Earnings Estimates - There have been no downward revisions for BSX's earnings estimates in the past two months, with one upward revision noted [3]. - The consensus estimate for BSX has also increased, reinforcing the bullish outlook for the stock [3]. Market Position - BSX is currently rated as a Zacks Rank 2 (Buy), indicating strong potential for continued growth [2].

1月7日，上交所连开两张"罚单"，分别对科创板公司亚辉龙、英集芯及有关责任人予以监管警示，原因为相关公司在披露涉及"脑机接口"业务信息时存 在不准确、不完整的情形。 | 证券代码 | 证券简称 | 监管类型 | 外理事由 | 涉及对象 | 外理日期 | | --- | --- | --- | --- | --- | --- | | 688575 | 亚辉龙 | 监管警示 | 关于深圳市亚辉龙生物科技股份有 | 上市公司,董秘 | 2026-01-07 | | | | | 限公司的决定书 | | | | 688209 | 英集示 | 监管警示 | 关于深圳英集芯科技股份有限公司 | 上市公司,董秘 | 2026-01-07 | | | | | 的地完书 | | | 亚辉龙1月6日股价上涨6.52%、成交量较前一个交易日增长299%。当天收盘后，该公司自愿披露与深圳脑机星链科技有限公司签订《战略合作框架协 议》，称双方将在产品研发、市场推广以及股权投资等方面开展合作，并披露后者为"深耕非侵入式与侵入式双技术路径的领先企业"。该公告披露后引 发市场关注，上交所火速下发问询函，要求公司说明合作具体情况。在监管督促下， ...

1月7日，上交所连开两张"罚单"，分别对科创板公司亚辉龙、英集芯及有关责任人予以监管警示，原因为相关公司在披露涉及"脑 机接口"业务信息时存在不准确、不完整的情形。 | 证券代码 | 证券简称 | 监管类型 | 外理事由 | 涉及对象 | 处理日期 | | --- | --- | --- | --- | --- | --- | | 688575 | 亚辉龙 | 监管警示 | 关于深圳市亚辉龙生物科技股份有 | 上市公司,董秘 | 2026-01-07 | | | | | 限公司的决定书 | | | | 688209 | 英集芯 | 监管警示 | 关于深圳英集芯科技股份有限公司 | 上市公司,董秘 | 2026-01-07 | | | | | 的决定书 | | | 亚辉龙1月6日晚自愿披露与脑机接口相关公司的框架协议，当晚收到上交所问询函，要求其进一步核实情况。另一家科创板公司英集芯也在1月 6日通过投资者互动平台透露关于脑机接口芯片领域的早期投资布局，因内容语焉不详，易引起误导，被上交所下发监管工作函。当前，两家公 司均已补充披露公告说明业务风险。 近期，"脑机接口"成为市场热点，多家公司股价连续涨停，引发监 ...